Arvinas is a clinical-stage biotechnology company that is at the forefront of targeted protein degradation therapeutics. Their mission is to enhance the lives of patients with serious illnesses by developing groundbreaking therapies using their innovative PROTAC® protein degradation platform. Arvinas is singularly dedicated to creating a completely new class of medicines that have the potential to be transformative for patients and healthcare providers.

By pushing the boundaries of drug discovery, Arvinas has positioned targeted protein degradation as one of the most promising fields in medical research. With a focus on oncology and neuroscience, their team is driving significant breakthroughs and building an extensive pipeline of potential treatments. Arvinas's proprietary PROTAC® protein degrader technology is based on the pioneering work of Dr.

Craig Crews at Yale University. Additionally, Arvinas values partnerships and collaborations with leading drug companies and academic experts to further accelerate clinical programs. Join Arvinas in revolutionizing drug discovery and bringing hope to patients in need